Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.72 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.68 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.53 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19260249 | 0.97 | HDAC1 (0.72) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL3856028 | 0.92 | HDAC6 (0.60) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL23950244 | 0.84 | HDAC1 (0.73) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL26159269 | 0.84 | HDAC1 (1.00) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL23950246 | 0.83 | HDAC1 (0.76) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL31476414 | 0.83 | HDAC1 (0.57) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL17502340 | 0.83 | HDAC1 (0.76) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL19278655 | 0.82 | HDAC1 (0.73) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL7019943 | 0.82 | HDAC6 (0.56) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL19260275 | 0.81 | HDAC1 (0.74) | HDAC1HDAC6HDAC8HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159463-A1 | BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI ZHONGZE THERAPEUTICS, CO. LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159463-A1 | BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI ZHONGZE THERAPEUTICS, CO. LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159463-A1 | BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | HDAC11, HDAC1, HDAC6 | HDAC1 2/4885HDAC6 3/4885HDAC8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.